Inhibition by sodium valproate of the arginine vasopressin and adrenocorticotropin responses to angiotensin II in normal men.
The present study was carried out in order to determine whether angiotensin II (ANG II) exerts its stimulatory effect on plasma concentration of arginine vasopressin (AVP) and adrenocorticotrophic hormone (ACTH) by interacting with a (gamma-aminobutyric acid) GABAergic pathway. For this purpose, the effect of the GABAergic agonist sodium valproate (600 mg in 3 divided doses p.o.) on the ACTH and AVP responses to ANG II (infusion for 60 min of successively increasing doses of 4, 8 and 16 ng/kg min; each dose for 20 min) administration was evaluated in 7 normal men. In all subjects control ANG II tests were performed with a placebo instead of sodium valproate. ANG II induced a significant increase of AVP at 60 min and ACTH at 90 min after the beginning of infusion. The pretreatment with sodium valproate reduced significantly both ANG II-induced AVP and ACTH rises, without changing the time course of the hormonal responses. These data suggest the involvement of a GABAergic mechanism in regulation of both AVP and ACTH responses to ANG II in man.
Coiro
V
V
Cattedra di Clinica Medica Generale, Università di Parma, Italy.
Chiodera
P
P
D000612:4-Aminobutyrate Transaminase / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000328:Adult; D000804:Angiotensin II / Q000494:pharmacology*; D001127:Arginine Vasopressin / Q000097:blood*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D008297:Male; D014635:Valproic Acid / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D004791:Enzyme Inhibitors; D000804:Angiotensin II; D001127:Arginine Vasopressin; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D000324:Adrenocorticotropic Hormone; D000612:4-Aminobutyrate Transaminase